key: cord-1039075-2jzfqx4d authors: Galindo, I.; Garaigorta, U.; Lasala, F.; Cuesta-Geijo, M.A.; Bueno, P.; Gil, C.; Delgado, R.; Gastaminza, P.; Alonso, C. title: Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses date: 2020-11-26 journal: Antiviral Res DOI: 10.1016/j.antiviral.2020.104990 sha: eb2920c742c6973445fcd737f45a9f9d08177239 doc_id: 1039075 cord_uid: 2jzfqx4d The endocytic pathway is a common strategy that several highly pathogenic viruses use to enter into the cell. To demonstrate the usefulness of this pathway as a common target for the development of broad-spectrum antivirals, the inhibitory effect of drug compounds targeting endosomal membrane proteins were investigated. This study entailed direct comparison of drug effectiveness against animal and human pathogenic viruses, namely Ebola (EBOV), African swine fever virus (ASFV), and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A panel of experimental and FDA-approved compounds targeting calcium channels and PIKfyve at the endosomal membrane caused potent reductions of entry up to 90% in SARS-CoV-2 S-protein pseudotyped retrovirus. Similar inhibition was observed against transduced EBOV glycoprotein pseudovirus and ASFV. SARS-CoV-2 infection was potently inhibited by selective estrogen receptor modulators in cells transduced with pseudovirus, among them Raloxifen inhibited ASFV with very low 50% inhibitory concentration. Finally, the mechanism of the inhibition caused by the latter in ASFV infection was analyzed. Overall, this work shows that cellular proteins related to the endocytic pathway can constitute suitable cellular targets for broad range antiviral compounds. The worldwide spread of COVID-19 (Coronavirus Disease 2019) highlights the 39 need for developing efficient therapeutics against severe acute respiratory 40 syndrome coronavirus 2 (SARS-CoV-2; (Gil et al., 2020) ). The disease was 41 declared a public health emergency and it is having an enormous impact on 42 human health and deep social and economic consequences. There are 43 several international efforts to develop vaccines in many vaccine platforms, 44 some of them undergoing clinical trials (Dagotto et al., 2020) . However, the 45 therapeutic arsenal to treat COVID-19 is limited to date, despite the research 46 efforts to develop effective and safe compounds (Gil et al., 2020) . Antiviral 47 Remdesivir, first developed against Ebola virus (EBOV), is a consistent 48 therapeutic option in severe COVID-19 patients approved by the FDA (Yin et 49 al., 2020) . Although several large drug screens have described antiviral 50 activity for a number of apparently unrelated FDA-approved compounds, it is 51 increasingly evident that a deeper understanding of the inhibitory mechanism 52 of antiviral compounds is needed to find useful and broad-spectrum antivirals 53 internal membrane with the endosomal membrane, naked cores are released to 117 the cytoplasm to start replication (Hernaez et al., 2016) . 118 Here, we examined the antiviral activity of a panel of experimental as well as 119 FDA-approved compounds acting on the endosomal membrane that could 120 constitute a potential target against SARS-CoV-2, EBOV, and ASFV because 121 although distant, all these viruses share similar entry pathways. Specifically, 122 tested compounds are known to act as PIKfyve inhibitors or as modifiers of 123 intracellular calcium levels with different degrees of knowledge with respect to 124 their antiviral activity. With the aim to decipher the specific inhibitory 125 mechanisms of some of these compounds, we further analyzed and compared 126 their inhibitory potential. (SARS-2-Spp) were produced in HEK293T cells following a previously 162 described procedure (Mingorance et al., 2014) We tested the inhibitory effect of the following compounds at the doses 203 conjugated secondary antibody and the ECL system (Amersham) using a 261 ChemidocXRS imaging system (Bio-Rad). Band densitometry was performed 262 with Image Lab software (BioRad) and data were normalized to control values. 263 To detect cholesterol accumulation, we used fluorescent filipin (Sigma). Filipin is 265 a naturally fluorescent polyene antibiotic that binds to cholesterol but not to 266 The experimental data were analyzed by one-way ANOVA by Graph Pad Prism 307 6 Software. Bonferroni´s correction was applied for multiple comparisons. 308 Values were expressed in graph bars as mean±SD of at least three 309 independent experiments and a p-value <0.05 was considered statistically 310 significant. 311 312 3. Results 313 We screened a collection of experimental as well as FDA-approved compounds 315 acting at the endosomal membrane searching for an antiviral effect. With this 316 aim, we included Tetrandrine (TETR), a specific TPC-1 and -2 endosomal 317 calcium channels inhibitor and also, Verapamil (VER) and other compounds, 318 which are not specific for endosomal channels but modify intracellular calcium 319 levels. Experimental drugs included as controls were Curcumin (CUR) that is a 320 regulator of intracellular calcium release from ER to endosomes (Bardak et al., Figure 1E ). Since PIKfyve and calcium channel inhibitors target the endocytic 385 pathway, which is a common route for several viruses, these may act as wide 386 spectrum antivirals. Apilimod exerted a potent inhibitory activity in pseudotyped 387 systems for SARS-CoV-2 spike (IC 50 <1), EBOV-GP, and against attenuated 388 ASFV (Fig. 1E-F) . However, also RLX and TMX caused a potent inhibitory 389 effect by an unknown mechanism. Remarkably, RLX exhibited an IC 50 of 0.91 390 for ASFV ( Figure 1F) . 391 The corresponding viability and dose/response curves are shown in 392 Supplementary Figure S2 -4 for Vero cells and for primary swine macrophages 393 in Figure S5 . 394 Then, we found that SERMs were potent antivirals, especially for ASFV, but 395 while the mechanism has been recently characterized for the other viruses, the 396 mechanism underlying the inhibitory effect of SERMs is not yet known for 397 ASFV. Then, we further studied their effect on ASFV infection. 398 Then, we further investigated the mechanism of inhibition caused by SERMs. The objective of this work was to study experimental and FDA-approved drugs 528 targeting functional proteins at the endosomal membrane as antiviral 529 candidates. These could inhibit a wide range of viruses, among them viruses of 530 humans, SARS-CoV-2 and EBOV, or animals, like ASFV. Our results highlight 531 the potential of endosomes in viral entry. However, it might be relevant to 532 consider other aspects of the vesicular transport machinery in which this 533 organelle participates such as, innate immunity, sorting, recycling, transport, 534 exit, metabolism, autophagy, chaperone-mediated degradation, and a handful 535 of other cellular processes. In general, endosomes function as major cellular 536 signaling hubs that are required for viral infections (Helenius, 2018) . All endosome-targeting compounds screened in this study, significantly reduced 551 the infectivity of SARS-CoV-2 S protein-pseudotyped retrovirus infection 552 efficiency in Vero E6 cells to a high degree. The most active compounds were 553 Apilimod and Tetrandrine over 99%, followed by Verapamil and Raloxifen over 554 90% ( Figure 1B) . The same drugs strongly reduced rVSV-EBOV-GP infectivity 555 compared with much less effect on rVSV-G ( Figure 1C-D) . Finally, we observed 556 entry reductions in ASFV infectivity over 80% using the following set of 557 compounds, APL, TETR, VER, and RLX ( Figure 1E) . The impact of these compounds was high on the three-virus screened, SARS-2-566 Spp retrovirus system, rVSV-EBOV-GP, rVSV-G and ASFV. However, TMX and 567 RLX caused a dose-dependent reduction of ASFV infectivity ca. 80-90% with 568 the lowest IC 50 value of 0.98. Hence, we further studied the potential 569 mechanism of action of SERMs on this virus. The decrease in ASFV infectivity 570 correlated with reductions on the expression of early viral protein p30 that 571 indicates that these drugs affected infection at very early stages. Viral 572 replication in the presence of these two components was also strongly inhibited. Ebola virus enters host cells by macropinocytosis 760 and clathrin-mediated endocytosis ICTV Virus Taxonomy Profile: Asfarviridae African swine fever virus-cell interactions: from virus entry to cell survival Curcumin regulates intracellular calcium 767 release and inhibits oxidative stress parameters, VEGF, and caspase-3/-9 levels in 768 human retinal pigment epithelium cells The 770 ubiquitin-proteasome system is required for African swine fever replication Ebola virus entry requires the cholesterol 775 transporter Niemann-Pick C1 SARS-CoV-2 Infection Depends on Cellular 782 Heparan Sulfate and ACE2 Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors Cholesterol Flux Is Required for Endosomal 789 Progression of African Swine Fever Virions during the Initial Establishment of Infection Endosomal maturation, Rab7 GTPase and phosphoinositides in African swine 793 fever virus entry Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection A mechanism for tamoxifen-mediated 798 inhibition of acidification Approaches and Challenges in SARS-CoV-2 800 Vaccine Development Rubella virus: first calcium-requiring viral fusion 802 protein Titration of African 804 swine fever (ASF) virus Clinically used 807 selective estrogen receptor modulators affect different steps of macrophage-specific 808 reverse cholesterol transport COVID-19: Drug Targets and 811 Potential Treatments Clinical 817 Characteristics of Coronavirus Disease 2019 in China Virus Entry: Looking Back and Moving Forward Dynamin-and clathrin-dependent endocytosis in African 821 swine fever virus entry African Swine Fever Virus 823 Undergoes Outer Envelope Disruption, Capsid Disassembly and Inner Envelope Fusion 824 before Core Release from Multivesicular Endosomes Small peptide 826 inhibitors disrupt a high-affinity interaction between cytoplasmic dynein and a viral 827 cargo protein SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 831 Clinically Proven Protease Inhibitor Clinical presentation, biochemical, and 835 haematological parameters and their association with outcome in patients with Ebola 836 virus disease: an observational cohort study Endosome maturation 839 Functional dissection of lipid and protein kinase signals of PIKfyve reveals the role of 840 PtdIns 3,5-P2 production for endomembrane integrity The Ongoing Ebola Epidemic in the Democratic Republic of Congo 845 Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-approved selective estrogen receptor modulators 850 inhibit Ebola virus infection Inhibition of PIKfyve kinase 853 prevents infection by Zaire ebolavirus and SARS-CoV-2 An Update on African Swine Fever Virology. 857 Viruses 11 Development of a TaqMan PCR assay with internal 860 amplification control for the detection of African swine fever virus Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order 864 in a Calcium-Dependent Manner Pocket similarity identifies selective estrogen receptor modulators as 867 microtubule modulators at the taxane site The V-type H+-ATPase in vesicular trafficking: 869 targeting, regulation and function Ebola virus and severe acute respiratory 872 syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ 873 endolysosomes is a rate-defining step Selective inhibition of hepatitis C 876 virus infection by hydroxyzine and benztropine Repurposing Estrogen Receptor Antagonists for the 879 Treatment of Infectious Disease The phosphatidylinositol-3-884 phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection Trop Dis 11 A Vaccine against Ebola Virus Characterization of 889 spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with 890 SARS-CoV Mining of Ebola virus entry 893 inhibitors identifies approved drugs as two-pore channel pore blockers Small rho GTPases and cholesterol biosynthetic pathway intermediates in 897 African swine fever virus infection Discovery of 905 SARS-CoV-2 antiviral drugs through large-scale compound repurposing Ebola virus. Two-pore channels 909 control Ebola virus host cell entry and are drug targets for disease treatment Cell entry 912 mechanisms of SARS-CoV-2 Inhibition of angiogenesis 914 by selective estrogen receptor modulators through blockade of cholesterol trafficking 915 rather than estrogen receptor antagonism Coronavirus 917 membrane fusion mechanism offers a potential target for antiviral development Regulation and isoform function of the V-920 Coronavirus biology and 922 replication: implications for SARS-CoV-2 Phosphoinositide conversion in endocytosis and the 924 endolysosomal system SARS 926 coronavirus entry into host cells through a novel clathrin-and caveolae-independent 927 endocytic pathway TPC proteins are 930 phosphoinositide-activated sodium-selective ion channels in endosomes and 931 lysosomes Broad Anti-coronavirus Activity of Food and Drug 934 Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo Fusion of Enveloped Viruses in Endosomes Generation of VSV pseudotypes using recombinant DeltaG-VSV for 939 studies on virus entry, identification of entry inhibitors, and immune responses to 940 vaccines Structural basis for inhibition of the RNA-946 dependent RNA polymerase from SARS-CoV-2 by remdesivir Toremifene interacts with and destabilizes the Ebola virus 949 glycoprotein Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the 952 Middle East Respiratory 953 Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome 954 Coronavirus (SARS-CoV) Aberrant 956 pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe 957 pulmonary syndrome patients of a new coronavirus (Tang et al., 2020) . It is to consider that SERMs could 617 also act as cationic amphiphilic drugs (CADs) causing alterations in acidification 618 and vesicular transport (Chen et al., 1999) . Moreover, this mechanism of action 619 would explain their inhibitory potential in the viruses under study indicating that 620 estrogen inhibitors could join some FDA-approved drugs potentially useful 621 against several viruses sharing this pathway, including SARS-CoV-2. 622